1. India Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Syngene International Limited

Syngene International Limited

SYNGENE.BO
Syngene International LimitedIN flagBombay Stock Exchange
435.55
INR
-3.05
- -
174.98BMarket Cap
Syngene International Limited
SYNGENE.BO
(Bombay Stock Exchange)

Recent

price

435.55

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
9.34
12.06
15.58
18.44
22.16
27.92
29.93
33.55
43.38
47.33
52.53
62.96
76.88
83.95
90.66
- -
92.82
Revenue per Share
0.8
2.1
2.95
3.59
4.6
6.19
7.35
7.74
8.38
10.38
10.18
9.94
11.59
12.71
12.35
- -
12.63
Basic EPS, GAAP
1.49
2.83
1.24
5.36
-4.87
0.35
2.34
2.09
1.19
0.86
6.4
2.64
7.62
13.24
9.89
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
2.99
0.51
- -
0.61
0.61
0.61
- -
- -
1
1.25
1.25
- -
- -
Dividend per Share
6.38
8.49
11.31
14.13
19.5
23.42
30.66
37.6
45.29
54.84
64.93
74.82
84.21
95.62
106.64
- -
- -
Book Value per Share
6.52
8.76
14.98
17.69
22.07
26.2
35.76
43.12
49.41
54.27
70.46
82.51
89.84
105.34
116.89
- -
- -
Tangible Book Value per Share
338
339
346
373
380
389
391
395
396
397
398
398
401
401
402
- -
402
Basic Weighted Avg Shares
3,160
4,085
5,395
6,871
8,427
10,856
11,695
13,245
17,156
18,797
20,891
25,067
30,802
33,695
36,424
37,387
37,272
Sales/Revenue/Turnover
16.8
22.82
27.51
28.21
25.6
27.73
23.17
20.3
21.89
20.44
18.56
17.33
20.07
19.2
16.78
14.08
17.3
Operating Margin (%)
515
547
599
656
814
973
1,143
1,314
1,642
2,193
2,745
3,097
3,665
4,259
4,326
4,529
4,369
Depreciation Expense
272
710
1,021
1,339
1,750
2,408
2,873
3,054
3,316
4,121
4,049
3,958
4,644
5,100
4,962
3,167
5,072
Net Income, GAAP
1.09
3.66
3.95
14
14
14.31
17.09
18.01
20.17
20.27
13.7
18.29
21.77
17.85
24.81
22.93
23.14
Effective Tax Rate (%)
8.61
17.38
18.92
19.49
20.77
22.18
24.57
23.06
19.33
21.92
19.38
15.79
15.08
15.14
13.62
8.47
13.61
Profit Margin (%)
-1,569
-823
880
1,716
1,106
8,007
9,238
9,366
6,355
734
6,737
9,770
12,371
8,147
8,909
5,905
- -
Working Capital
- -
42
- -
- -
186
7,252
6,898
5,855
3,617
812
6,176
7,417
7,032
4,651
4,088
3,985
- -
LT Debt
2,207
2,968
5,186
6,593
8,449
10,247
14,131
17,204
19,684
21,758
28,214
32,976
36,180
42,577
47,268
48,391
- -
Total Equity
13.26
22.53
30.77
25.03
20.39
17.57
10.77
9.25
11.3
10.66
10.02
8.81
11.03
11.45
9.06
7.64
- -
Return on Invested Capital (%)
8.09
18.87
26.4
24.99
22.24
17.87
15.73
15.06
14.66
15.83
13.35
10.97
12
12.75
11.58
12.38
54.2
Return on Capital (%)
13.43
28.2
30.07
29.17
27.6
29.15
27.25
22.77
20.25
20.77
17.01
14.23
14.62
14.14
12.22
13.51
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'25
Jun'26
ST Debt
- -
1,691
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
4,088
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
401
- -
Market Capitalization
344,175
291,405
256,526

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'25
Jun'26
Total Current Assets
- -
22,873
- -
Cash, Cash Equivalents & STI
- -
13,973
- -
Accounts Receivable, Net
- -
5,268
- -
Inventories
- -
1,555
- -
Total Current Liabilities
- -
13,964
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
1,691
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
17.2%
11.54%
2.38%
Free Cash Flow
136.32%
43.63%
37.61%
Net Income, GAAP
4.27%
-2.8%
-36.17%
Sales/Revenue/Turnover
13.42%
12.6%
2.64%
Total Cash Common Dividend
- -
- -
0.2%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
8,081
9,101
8,535
7,978
33,695
2025
7,897
8,910
9,437
10,180
36,424
2026
8,745
9,171
10,365
- -
37,387

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2.33
2.9
2.78
- -
12.71
2025
1.89
2.64
3.27
4.56
12.35
2026
2.16
0.37
3.68
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1.25
2025
- -
- -
- -
- -
1.25
2026
- -
- -
- -
- -
- -
Similar Companies
Futura Medical plc (FUM.L)
BioLineRx Ltd. (BLRX.TA)
RVL Pharmaceuticals plc (OSMT)
Lyka Labs Limited (LYKALABS.NS)
Cynata Therapeutics Limited (CYYNF)
KALA BIO, Inc. (0JQ2.L)
Business
Syngene International Limited, a leading global contract research, development and manufacturing organization (CRDMO) and subsidiary of Biocon Limited, provides integrated end-to-end scientific services from early-stage discovery to commercial manufacturing for pharmaceutical, biotechnology, agrochemical, animal health, nutrition, consumer goods, cosmetics and specialty materials sectors; its core offerings encompass discovery chemistry including synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science and computational chemistry; discovery biology spanning recombinant DNA engineering, cell line development, protein sciences, screening, assay biology, DMPK, in vivo pharmacology, toxicology and biologicals; development services such as lead generation, preclinical development, API and drug product development, chemical and formulation development, clinical trial management, pharmacokinetic analysis, biometrics, pharmacovigilance and medical writing; manufacturing services featuring cGMP-compliant facilities for clinical supplies, registration batches and commercial production of small molecules, biologics, peptides, oligonucleotides and antibody-drug conjugates; and dedicated R&D centers like SynVent for integrated drug discovery platforms and specialized centers for clients such as Bristol-Myers Squibb, Baxter, Amgen and Herbalife Nutrition. The company operates primary facilities in Bengaluru, Hyderabad and Mangaluru in India, with business development offices in the US (Cambridge, MA) and UK (Cheshire), and serves over 300 clients across North America, Europe, Japan, Australia and other regions. Founded in 1993 and headquartered in Bengaluru, India, Syngene recently concluded its acquisition of a biologics manufacturing facility in Baltimore, US, from Emergent BioSolutions in March 2025 for $36.5 million, boosting its single-use bioreactor capacity to 50,000 liters and enabling onshore production for US mAb developers and animal health clients starting H2 2025; it announced plans in October 2025 to add a bioconjugation suite for end-to-end ADC development and invest in a dedicated peptide laboratory with advanced automation; and earned recognition as one of the World's Most Sustainable Companies 2025 by TIME Magazine and Statista.